FAM86LP

Across TCGA pan-cancer cohorts, FAM86LP RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of FAM86LP’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where FAM86LP RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FAM86LP is over-expressed in tumor, although a few such as LIHC show the opposite, repressed pattern.

LUAD, STAD, and BRCA are the cancer types where FAM86LP tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM86LP RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	II,III,IV	+0.342	<.001	11	view →
STAD	All	II,III,IV	+0.271	<.001	6	view →
BRCA	All	II,III,IV	+0.072	.023	4	view →
PAAD	Male	All	+0.280	.019	2	view →
LIHC	Female	All	−0.023	.009	2	view →
ESCA	Female	All	+0.203	.036	1	view →
CHOL	Male	All	+0.133	.042	1	view →
KIRC	All	IV	+0.057	.020	1	view →
KIRP	All	All	+0.046	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

FAM86LP–LUAD

Open the LUAD breakdown →